Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

Gregory L. Weaver net worth and biography

Gregory Weaver Biography and Net Worth

CFO of Atai Life Sciences

Gregory L. Weaver serves as Independent Director of the Company. Mr. Weaver served as Chief Financial Officer of Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) a publicly traded biotech company from September 2017 to March 2020. Mr. Weaver previously served as the Chief Financial Officer from October 2015 to August 2017 with ProMetic Life Sciences, and from January to October 2015 with Oryzon Genomics. Mr. Weaver received his undergraduate degree in finance from Trinity University and his MBA from Boston College. Mr. Weaver has been selected to serve on the Company’s Board of Directors because of his qualifications as a business executive and audit committee financial expert, and his current and prior experience as a Chief Financial Officer, director and committee member of public companies. From 2014 to January 2020, Mr. Weaver served on the board of directors of Egalet Corp., a publicly traded biotech company, and from September 2014 to January 2015 on the board of directors of Oryzon Genomics, a publicly traded biotech company.

How do I contact Gregory L. Weaver?: The corporate mailing address for Mr. Weaver and other Atai Life Sciences executives is c/o Mindspace Krausenstra sse 9-10, Berlin, Berlin 10117. Atai Life Sciences can also be reached via phone at 49-89-2153-9035 and via email at [email protected]. Learn More on Gregory L. Weaver's contact information.
Has Gregory L. Weaver been buying or selling shares of Atai Life Sciences?: Gregory L. Weaver has not been actively trading shares of Atai Life Sciences during the last ninety days. Learn More on Gregory L. Weaver's trading history.
Who are Atai Life Sciences' active insiders?: Atai Life Sciences' insider roster includes Christian Angermayer (Director), Srinivas Rao (Insider), and Gregory Weaver (CFO). Learn More on Atai Life Sciences' active insiders.
Are insiders buying or selling shares of Atai Life Sciences?: During the last year, Atai Life Sciences insiders bought shares 2 times. They purchased a total of 60,000 shares worth more than $81,200.00. During the last year, insiders at the sold shares 2 times. They sold a total of 89,050 shares worth more than $164,742.50. The most recent insider tranaction occured on April, 2nd when CFO Anne Nagengast Johnson sold 27,410 shares worth more than $50,708.50. Insiders at Atai Life Sciences own 30.0% of the company. Learn More about insider trades at Atai Life Sciences.
Information on this page was last updated on 4/2/2024.

Gregory L. Weaver Insider Trading History at Atai Life Sciences

Gregory L. Weaver Buying and Selling Activity at Atai Life Sciences

Atai Life Sciences Company Overview

ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Today's Range

Now: $1.92

$1.83

$1.93

50 Day Range

MA: $1.98

$1.63

$2.60

2 Week Range

Now: $1.92

$1.03

$2.85

Volume

575,519 shs

Average Volume

1,693,778 shs

Market Capitalization

$321.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.98